JP2014518276A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518276A5
JP2014518276A5 JP2014519158A JP2014519158A JP2014518276A5 JP 2014518276 A5 JP2014518276 A5 JP 2014518276A5 JP 2014519158 A JP2014519158 A JP 2014519158A JP 2014519158 A JP2014519158 A JP 2014519158A JP 2014518276 A5 JP2014518276 A5 JP 2014518276A5
Authority
JP
Japan
Prior art keywords
composition
concentration
isolated polypeptide
arginine
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014519158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518276A (ja
JP6463968B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/044988 external-priority patent/WO2013006454A1/en
Publication of JP2014518276A publication Critical patent/JP2014518276A/ja
Publication of JP2014518276A5 publication Critical patent/JP2014518276A5/ja
Application granted granted Critical
Publication of JP6463968B2 publication Critical patent/JP6463968B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014519158A 2011-07-01 2012-06-29 アルギニンを含まない腫瘍壊死因子受容体:fc融合ポリペプチド組成物およびその使用方法 Active JP6463968B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161504110P 2011-07-01 2011-07-01
US61/504,110 2011-07-01
PCT/US2012/044988 WO2013006454A1 (en) 2011-07-01 2012-06-29 Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017098806A Division JP2017186349A (ja) 2011-07-01 2017-05-18 アルギニンを含まない腫瘍壊死因子受容体:fc融合ポリペプチド組成物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2014518276A JP2014518276A (ja) 2014-07-28
JP2014518276A5 true JP2014518276A5 (cg-RX-API-DMAC7.html) 2015-08-13
JP6463968B2 JP6463968B2 (ja) 2019-02-06

Family

ID=46579322

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014519158A Active JP6463968B2 (ja) 2011-07-01 2012-06-29 アルギニンを含まない腫瘍壊死因子受容体:fc融合ポリペプチド組成物およびその使用方法
JP2017098806A Pending JP2017186349A (ja) 2011-07-01 2017-05-18 アルギニンを含まない腫瘍壊死因子受容体:fc融合ポリペプチド組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017098806A Pending JP2017186349A (ja) 2011-07-01 2017-05-18 アルギニンを含まない腫瘍壊死因子受容体:fc融合ポリペプチド組成物およびその使用方法

Country Status (13)

Country Link
US (2) US10995130B2 (cg-RX-API-DMAC7.html)
EP (1) EP2726090B1 (cg-RX-API-DMAC7.html)
JP (2) JP6463968B2 (cg-RX-API-DMAC7.html)
KR (1) KR102061355B1 (cg-RX-API-DMAC7.html)
CN (2) CN103930124B (cg-RX-API-DMAC7.html)
AU (2) AU2012279205B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013033671B1 (cg-RX-API-DMAC7.html)
CA (1) CA2840711C (cg-RX-API-DMAC7.html)
DK (1) DK2726090T3 (cg-RX-API-DMAC7.html)
EA (1) EA026226B1 (cg-RX-API-DMAC7.html)
MX (2) MX358137B (cg-RX-API-DMAC7.html)
WO (1) WO2013006454A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201400490B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351269B1 (en) 2005-06-14 2020-01-29 Amgen Inc. Self-buffering protein formulations
RU2642310C2 (ru) * 2011-06-28 2018-01-24 ИНХИБРКС ЭлЭлСи Слитые серпиновые полипептиды и способы их применения
MX358137B (es) 2011-07-01 2018-08-06 Biogen Idec Inc Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso.
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
CN104010654B (zh) * 2011-10-18 2017-10-27 科荣生生物科学公司 金属离子稳定的依那西普制剂
HK1209343A1 (en) * 2012-07-09 2016-04-01 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
WO2014039903A2 (en) 2012-09-07 2014-03-13 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
HRP20180182T1 (hr) 2012-09-11 2018-04-20 Coherus Biosciences, Inc. Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa
JP6026002B2 (ja) * 2012-11-27 2016-11-16 アルテオジェン インコーポレイテッド タンパク質とFcドメインを融合した融合タンパク質の安定化用組成物
JP2016518386A (ja) * 2013-05-02 2016-06-23 マブキシェンス エス.アー. TNFR:Fc融合ポリペプチドの代替配合物
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Meiji Seikaファルマ株式会社 安定化されたポリペプチド水性製剤
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
ES2600488T3 (es) 2014-05-23 2017-02-09 Ares Trading S.A. Composición farmacéutica líquida
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HK1244685A1 (zh) 2014-12-22 2018-08-17 阿雷斯贸易股份有限公司 液体药物组合物
KR20170138426A (ko) * 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
EP3533441A4 (en) * 2016-10-28 2019-12-04 Celltrion Inc. STABLE PHARMACEUTICAL FORMULATION
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201901547D0 (en) 2019-02-05 2019-03-27 Arecor Ltd Stabilized Fc Fusion protein solutions
EP4404979A4 (en) * 2021-09-22 2025-10-08 Sirnaomics Inc PHARMACEUTICAL COMPOSITIONS OF NANOPARTICLES WITH REDUCED NANOPARTICLE SIZE AND IMPROVED POLYDISPERSITY INDEX

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
EP1475101B1 (en) 2002-02-14 2010-10-27 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
EP3210624A1 (en) * 2002-02-27 2017-08-30 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
KR100471843B1 (ko) 2002-06-11 2005-03-08 현대자동차주식회사 자동차의 아웃사이드 웨더스트립 장착구조
DK2236154T3 (en) 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
PL213501B1 (pl) 2003-02-28 2013-03-29 Ares Trading Sa Wodny preparat bialka wiazacego czynnik martwicy nowotworu i sposób jego wytwarzania
JP2007521315A (ja) * 2003-08-01 2007-08-02 アムジェン インコーポレイテッド 結晶性腫瘍壊死因子レセプター2ポリペプチド
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
EP3351269B1 (en) 2005-06-14 2020-01-29 Amgen Inc. Self-buffering protein formulations
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
US20080003220A1 (en) * 2006-04-21 2008-01-03 Amgen, Inc. Buffering agents for biopharmaceutical formulations
MX2009003982A (es) 2006-10-20 2009-04-27 Amgen Inc Formulaciones de polipeptido estables.
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
CN101969971A (zh) * 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
EP2598167B1 (en) * 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
MX358137B (es) 2011-07-01 2018-08-06 Biogen Idec Inc Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso.

Similar Documents

Publication Publication Date Title
JP2014518276A5 (cg-RX-API-DMAC7.html)
RU2013151303A (ru) СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc
EP2726090B1 (en) Arginine - free tnfr : fc- fusion polypeptide compositions
CN103998060B (zh) 使用糖与多元醇的结合物稳定的依那西普制剂
JP2013518055A5 (cg-RX-API-DMAC7.html)
BR112015010235B1 (pt) formulação líquida de um conjugado de derivado de oxintomodulina de longa duração e método para a preparação da mesma
JP2022166006A (ja) 液体医薬組成物
RU2015151606A (ru) Альтернативные составы для химерных полипептидов tnfr:fc
JPWO2015190378A1 (ja) 安定なアダリムマブ水性製剤
EP2869816A1 (en) Etanercept formulations exhibiting marked reduction in sub-visible particles
WO2015064591A1 (ja) タンパク質水性懸濁剤
JP2012530770A5 (cg-RX-API-DMAC7.html)
TWI728409B (zh) Hgf冷凍乾燥製劑
CN104936607A (zh) 稳定的TNFR:Fc融合蛋白药物组合物
JP2016502528A (ja) タンパク質とFcドメインを融合した融合タンパク質の安定化用組成物
WO2014178216A1 (ja) 水溶液製剤およびその製造方法
CN102441172B (zh) 高纯度凝血酶原复合物制品冷冻干燥稳定剂
JP2013510158A5 (cg-RX-API-DMAC7.html)
US9821059B2 (en) Composition for stabilizing protein and pharmaceutical formulation comprising the same
JP2016084329A (ja) 振とうストレス耐性を有するタンパク質の水性懸濁剤
TW201607564A (zh) 經安定化的多肽水性製劑
HK1200720B (en) Etanercept formulations stabilized with combinations of sugars and polyols
JPWO2023064886A5 (cg-RX-API-DMAC7.html)